A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
Launched by HOFFMANN-LA ROCHE · Sep 24, 2015
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults at least 18 years of age
- • Malignant bone disease due to multiple myeloma or cancer of the lung, prostate, gastrointestinal (GI) tract, ovary, or bladder
- • Bone pain defined as a Brief Pain Inventory (BPI) most acute pain score greater than or equal to 4
- • Radiologically confirmed bone disease disease
- Exclusion Criteria:
- • Previous treatment with ibandronate (Bondronat) within previous 2 months
- • Severely impaired renal function
- • Known brain metastases
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Plovdiv, , Bulgaria
Sofia, , Bulgaria
Pleven, , Bulgaria
Plovdiv, , Bulgaria
Haskovo, , Bulgaria
Vratza, , Bulgaria
Bourgas, , Bulgaria
Varna, , Bulgaria
Sofia, , Bulgaria
Patients applied
Trial Officials
Clinical Trials
Study Chair
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials